Why is Natco Pharma falling/rising?

Recent Price Movement and Market Context

Natco Pharma's share price has been under pressure over the past week, registering a decline of 7.17%, significantly underperforming the broader Sensex index, which fell by only 0.84% in the same period. This underperformance is further highlighted by the stock's four consecutive days of losses, accumulating an 8.57% drop in returns during this stretch. Intraday trading on 10-Dec saw the stock touch a low of ₹864.50, marking a 3.18% dip from previous levels.

Despite this short-term weakness, the stock has shown resilience over the past month with an 8.65% gain, outperforming the Sensex's 1.02% rise. However, the longer-term picture remains challenging. Year-to-date, Natco Pharma's shares have declined by 37.45%, contrasting sharply with the Sensex's 8.00% gain. Over the last year, the stock has fallen by 41.76%, while the benchmark index has advanced by 3.53%. Even over five years, the stock has underperformed, declining by 9.59% compared to the Sensex's robust 83.62% growth.

Technical Indicators and Investor Activity

From a technical standpoint, Natco Pharma's current price remains above its 50-day and 200-day moving averages, suggesting some underlying support at longer-term levels. However, it is trading below its 5-day, 20-day, and 100-day moving averages, indicating short- to medium-term weakness. This mixed technical picture may be contributing to investor uncertainty.

Investor participation has notably declined, with delivery volumes on 9-Dec falling by 57.06% compared to the five-day average. This reduction in trading activity suggests waning enthusiasm or caution among shareholders, which often exacerbates price declines during downtrends. Despite this, liquidity remains adequate, with the stock capable of supporting trades worth approximately ₹2.78 crores based on 2% of the five-day average traded value.

Fundamental Factors Influencing the Stock

Natco Pharma's fundamentals present a mixed picture. The company boasts a strong management efficiency, reflected in a return on equity (ROE) of 16.25%, and maintains a low debt-to-equity ratio averaging zero, indicating a conservative capital structure. Its valuation metrics are relatively attractive, with a price-to-book value of 1.8, suggesting the stock is trading near fair value compared to historical peer averages.

However, the company’s profitability has been under pressure. Over the past year, profits have declined by 20.9%, a significant contraction that has weighed heavily on investor sentiment. This profit decline aligns with the stock’s 41.76% negative return over the same period, signalling that earnings challenges are a key driver behind the share price weakness.

Conclusion: Why Natco Pharma Is Falling

The recent decline in Natco Pharma’s share price is primarily attributable to its deteriorating profit performance and cautious investor behaviour. Despite solid management efficiency and a conservative balance sheet, the significant drop in profits over the last year has undermined confidence. This has been compounded by reduced trading volumes and the stock’s failure to sustain momentum above key short-term moving averages.

While the stock remains fairly valued and retains some long-term technical support, the prevailing market sentiment is negative, as reflected in the stock’s underperformance relative to the Sensex and its sector peers. Investors appear to be adopting a wait-and-see approach amid ongoing earnings challenges, resulting in the recent price weakness.

For those considering exposure to Natco Pharma, it is essential to weigh the company’s strong management and low leverage against the current profit headwinds and subdued market interest. Monitoring upcoming earnings reports and sector developments will be crucial to assessing whether the stock can regain upward momentum.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →